Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX9930 in C3G, IgAN, or PMN
NCT05162066Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Feb 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of vimircopan in Complement 3 glomerulopathy (C3G), IgA nephropathy (IgAN) and primary membranous nephropathy (PMN) (3 cohorts), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Percent Change From Baseline in 24-hour Urine Protein-to-Creatinine Ratio at 24 weeks. Started Feb 2022; status: terminated.
02
Drugs
vimircopan
03
Conditions
Complement 3 glomerulopathy (C3G)IgA nephropathy (IgAN)primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05162066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162066.